HCAT — Health Catalyst Income Statement
0.000.00%
Last trade - 00:00
- $353.13m
- $263.44m
- $295.94m
- 55
- 57
- 48
- 53
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 155 | 189 | 242 | 276 | 296 |
Cost of Revenue | |||||
Gross Profit | 80.9 | 90.8 | 118 | 134 | 135 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 211 | 293 | 386 | 416 | 423 |
Operating Profit | -56.5 | -105 | -144 | -140 | -127 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -60 | -116 | -160 | -142 | -118 |
Provision for Income Taxes | |||||
Net Income After Taxes | -60.1 | -115 | -153 | -137 | -118 |
Net Income Before Extraordinary Items | |||||
Net Income | -60.1 | -115 | -153 | -137 | -118 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -241 | -115 | -153 | -137 | -118 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -12.8 | -2.72 | -2.82 | -2.45 | -1.63 |